320 related articles for article (PubMed ID: 26402468)
21. Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
Li Z; Xu X; Li Y; Zou K; Zhang Z; Xu X; Liao Y; Zhao X; Jiang W; Yu W; Guo W; Chen Y; Li Y; Chen M; Deng WG; Li L; Zou L
Cell Physiol Biochem; 2018; 45(5):1772-1786. PubMed ID: 29495002
[TBL] [Abstract][Full Text] [Related]
22. Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
Sahin I; Azab F; Mishima Y; Moschetta M; Tsang B; Glavey SV; Manier S; Zhang Y; Sacco A; Roccaro AM; Azab AK; Ghobrial IM
Am J Hematol; 2014 Nov; 89(11):1030-6. PubMed ID: 25060991
[TBL] [Abstract][Full Text] [Related]
23. PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541.
Hägerstrand D; Lindh MB; Peña C; Garcia-Echeverria C; Nistér M; Hofmann F; Ostman A
Neuro Oncol; 2010 Sep; 12(9):967-75. PubMed ID: 20378689
[TBL] [Abstract][Full Text] [Related]
24. Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines.
Nölting S; Garcia E; Alusi G; Giubellino A; Pacak K; Korbonits M; Grossman AB
J Mol Endocrinol; 2012 Oct; 49(2):79-96. PubMed ID: 22715163
[TBL] [Abstract][Full Text] [Related]
25. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
26. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
Scotlandi K; Manara MC; Nicoletti G; Lollini PL; Lukas S; Benini S; Croci S; Perdichizzi S; Zambelli D; Serra M; García-Echeverría C; Hofmann F; Picci P
Cancer Res; 2005 May; 65(9):3868-76. PubMed ID: 15867386
[TBL] [Abstract][Full Text] [Related]
28. Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.
Geuna E; Milani A; Martinello R; Aversa C; Valabrega G; Scaltriti M; Montemurro F
Expert Opin Investig Drugs; 2015 Mar; 24(3):421-31. PubMed ID: 25645727
[TBL] [Abstract][Full Text] [Related]
29. Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma.
Trautmann M; Cyra M; Isfort I; Jeiler B; Krüger A; Grünewald I; Steinestel K; Altvater B; Rossig C; Hafner S; Simmet T; Becker J; Åman P; Wardelmann E; Huss S; Hartmann W
Mol Cancer Ther; 2019 Apr; 18(4):834-844. PubMed ID: 30787173
[TBL] [Abstract][Full Text] [Related]
30. NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.
Park E; Park J; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
Int J Oncol; 2012 Apr; 40(4):1259-66. PubMed ID: 22159814
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
32. Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors.
Chanal M; Chevallier P; Raverot V; Fonteneau G; Lucia K; Monteserin Garcia JL; Rachwan A; Jouanneau E; Trouillas J; Honnorat J; Auger C; Theodoropoulou M; Raverot G
Mol Cancer Ther; 2016 Jun; 15(6):1261-70. PubMed ID: 26983879
[TBL] [Abstract][Full Text] [Related]
33. The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Al-Ali R; Krake S; Radefeldt M; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457111
[TBL] [Abstract][Full Text] [Related]
34. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.
Renshaw J; Taylor KR; Bishop R; Valenti M; De Haven Brandon A; Gowan S; Eccles SA; Ruddle RR; Johnson LD; Raynaud FI; Selfe JL; Thway K; Pietsch T; Pearson AD; Shipley J
Clin Cancer Res; 2013 Nov; 19(21):5940-51. PubMed ID: 23918606
[TBL] [Abstract][Full Text] [Related]
35. Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.
Ramakrishnan V; Kimlinger T; Haug J; Painuly U; Wellik L; Halling T; Rajkumar SV; Kumar S
PLoS One; 2012; 7(11):e50005. PubMed ID: 23185517
[TBL] [Abstract][Full Text] [Related]
36. Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line.
Ayub A; Yip WK; Seow HF
Biomed Pharmacother; 2015 Oct; 75():40-50. PubMed ID: 26463630
[TBL] [Abstract][Full Text] [Related]
37. Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling.
He X; Wang Y; Zhu J; Orloff M; Eng C
Cancer Lett; 2011 Feb; 301(2):168-76. PubMed ID: 21168265
[TBL] [Abstract][Full Text] [Related]
38. Phosphatidylinositol-3'-kinase/AKT signaling is essential in synovial sarcoma.
Friedrichs N; Trautmann M; Endl E; Sievers E; Kindler D; Wurst P; Czerwitzki J; Steiner S; Renner M; Penzel R; Koch A; Larsson O; Tanaka S; Kawai A; Schirmacher P; Mechtersheimer G; Wardelmann E; Buettner R; Hartmann W
Int J Cancer; 2011 Oct; 129(7):1564-75. PubMed ID: 21128248
[TBL] [Abstract][Full Text] [Related]
39. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
Zitzmann K; Rüden Jv; Brand S; Göke B; Lichtl J; Spöttl G; Auernhammer CJ
Cancer Lett; 2010 Sep; 295(1):100-9. PubMed ID: 20356670
[TBL] [Abstract][Full Text] [Related]
40. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.
Vujic I; Sanlorenzo M; Posch C; Esteve-Puig R; Yen AJ; Kwong A; Tsumura A; Murphy R; Rappersberger K; Ortiz-Urda S
Oncotarget; 2015 Jan; 6(2):969-78. PubMed ID: 25504439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
